Southeast Asia's Healthcare and Laboratory Revolution in 2026 – Strengthening Infection Control Through Advanced Specimen Bag and Lab Packaging Solutions
- Meritplas | Merit Packaging
- Jun 22
- 8 min read
Introduction – A Transformative Year for Healthcare in Southeast Asia
The year 2026 marks a pivotal moment for healthcare and laboratory infrastructure across Southeast Asia. From groundbreaking plasma therapy ecosystems to new infectious disease laboratories, from AI-powered diagnostics to strengthened medical waste regulations, the region is undergoing a profound transformation that places infection control at the forefront of public health priorities.
At the heart of this transformation lies an often-overlooked but essential component: specimen bags, specimen transport bags with pouch, lab packaging, and biohazard bags. These seemingly simple products are the first line of defense in infection control – protecting healthcare workers, laboratory staff, patients, and communities from exposure to infectious materials.
As a trusted Malaysia-based manufacturer of healthcare and laboratory packaging solutions since 1983, Merit Packaging Sdn Bhd (Meritplas) is proud to support this regional healthcare revolution with high-quality specimen bags, specimen transport bags with pouch, lab packaging, and biohazard bags that meet the highest international standards of safety and infection control.
Malaysia Leads the Way with National Infection Prevention and Control Action Plan
In a significant development for infection control across the region, Malaysia has taken bold steps to strengthen its healthcare infrastructure. In May 2026, the Ministry of Health Malaysia convened the Malaysian Action Plan on Infection Prevention and Control (MyAPIPC) 2026-2030 workshop at the Putrajaya International Convention Centre. This national action plan aligns with the WHO Global Action Plan on Infection Prevention and Control 2024-2030 and brings together experts in infectious diseases, family health, and clinical microbiology to develop strategic priorities across eight key directions.
The development of MyAPIPC reflects a growing recognition across Southeast Asia that infection control is not merely a clinical concern but a national security imperative. As healthcare systems expand and new infectious disease threats emerge – including dengue, Nipah virus, and hantavirus – the need for robust infection prevention measures has never been more urgent.
How Meritplas Supports Malaysia's Infection Control Goals: Our specimen bags and specimen transport bags with pouch are engineered with leak-proof seals and tamper-evident features, ensuring that biological samples are safely contained from collection to laboratory analysis. Our biohazard bags – available in internationally recognized red, orange, and yellow color codes – provide secure containment of infectious waste, supporting healthcare facilities in meeting the stringent requirements of national infection control protocols.
Laboratory Infrastructure Expansion Across the Region
2026 has witnessed remarkable investments in laboratory infrastructure across Southeast Asia, driving unprecedented demand for high-quality lab packaging and specimen bags.
Philippines – New Biosafety Level 2 Infectious Disease Laboratory
In July 2026, the Ilocos Training and Regional Medical Center (ITRMC), in partnership with the Department of Health and the Asian Development Bank, inaugurated a P33.69-million Biosafety Level 2 (BSL-2) Infectious Disease Referral Laboratory. This facility enhances the region's capacity to provide advanced diagnostic services, including polymerase chain reaction (PCR) testing, microbiology, and virology – enabling faster, safer, and more responsive laboratory testing while reducing the need to refer specimens to national reference laboratories.
The laboratory will also serve as a center for learning, research, and capacity development, providing healthcare professionals with opportunities to refine their expertise in molecular diagnostics, microbiology, and virology.
Malaysia – RM175 Million Pathology Laboratory
Malaysia is investing heavily in diagnostic capacity. The Raja Perempuan Zainab Hospital II (HRPZ II) in Kelantan will receive a new RM175 million pathology laboratory, significantly expanding the region's diagnostic capabilities.
Singapore – Merck Expands BioReliance Biosafety Testing Laboratory
In August 2026, Merck announced the expansion of its Singapore BioReliance laboratory, introducing the Asia-Pacific's first GMP-compliant next-generation sequencing (NGS) laboratory. The expanded facility, covering over 1,000 square meters, provides cell line characterization, GMP next-generation sequencing, and molecular testing services – including the Blazar® rapid virus detection platform for biologics quality control.
How Meritplas Supports Laboratory Expansion: As laboratories across Southeast Asia expand their operations, the demand for reliable specimen bags, specimen transport bags with pouch, and lab packaging grows exponentially. Our products are manufactured under ISO 9001:2015 certified quality management systems, ensuring that laboratories can trust the integrity of the packaging they use for specimen collection, transport, and storage.
Diagnostic Innovation – Home-Grown Rapid Tests and AI-Powered Detection
Southeast Asian nations are investing in diagnostic innovation to reduce reliance on imported testing kits and build domestic capacity.
Vietnam – Flexible Rapid Diagnostic Test Platform
Vietnamese scientists at the Vietnam-Korea Institute of Science and Technology (VKIST) are developing a flexible rapid-test platform capable of detecting viruses, bacteria, and cancer biomarkers. Using lateral flow immunoassay (LFIA) technology, the platform allows researchers to adapt the system to new pathogens or testing requirements by changing the relevant antibodies while retaining much of the existing manufacturing process.
The team has developed prototypes targeting H5N1 influenza, hepatitis B, E. coli, Pseudomonas, and Klebsiella, as well as cancer biomarkers including carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and prostate-specific antigen (PSA). A two-colour test strip developed by the team was granted Utility Solution Patent No. 4859 in March 2026.
Thailand – AI-Enabled Tuberculosis Screening
Thailand's National Science and Technology Development Agency (NSTDA) has advanced SERS-TB, an AI-enabled Raman screening technology for latent tuberculosis infection (LTBI), supporting faster and more accessible disease surveillance.
Singapore – AI-Powered Antibiotic Resistance Test
Singapore General Hospital (SGH) and A*STAR's Diagnostics Development (DxD) Hub are commercializing an AI-powered test kit that helps doctors determine which combinations of antibiotics work best against drug-resistant infections – a critical tool in the fight against antimicrobial resistance.
How Meritplas Supports Diagnostic Innovation: As new diagnostic technologies emerge, the need for reliable specimen bags and specimen transport bags with pouch remains constant. Our specimen transport bags with pouch feature a separate, integrated pouch for storing accompanying documentation – such as test requisition forms or patient records – outside the main specimen compartment, reducing contamination risk and improving chain of custody. This design is particularly valuable for the complex diagnostic workflows emerging from these innovations.
Medical Waste Management – New Regulations Drive Demand for Biohazard Bags
Across Southeast Asia, medical waste management regulations are being strengthened, driving increased demand for compliant biohazard bags and clinical waste bags.
ASEAN-Wide Harmonization
The ASEAN Secretariat released new guidelines on medical waste cross-border transport in 2025, requiring member states to unify waste classification codes and tracking systems by 2026. This has created demand for digital waste management platforms and standardized packaging solutions. Nine ASEAN member states have completed revisions to their National Action Plans (NAPs) on medical waste management, adding specific controls for special waste categories including mercury-containing waste and cytotoxic waste.
Indonesia – Electronic Tracking and High-Potency Pharmaceutical Waste Crackdown
Indonesia implemented new regulations in January 2026, requiring all healthcare facilities with 300 beds to maintain at least 40 waste segregation bins. The Ministry of Environment and Forestry now mandates electronic manifests ("Festronik") with GPS tracking for every hazardous (B3) waste shipment. High-potency pharmaceutical wastes – including anticancer cytotoxics and mutagenic drugs – are classified as B3 hazardous waste under Indonesia's Environmental Protection Law.
Thailand – Stricter Emission Standards
Thailand implemented new medical waste incinerator emission standards in April 2026, tightening dioxin limits from 0.1 ng TEQ/Nm³ to 0.05 ng TEQ/Nm³.
Vietnam – Thermal Disinfection Standards
Vietnam's National Technical Regulation on thermal disinfection of infectious healthcare waste (QCVN 55:2025/BNNMT) took effect on January 19, 2026. Ho Chi Minh City is also piloting subcritical water technology to process medical and hazardous waste as part of its 2025-2030 environmental targets.
Malaysia – Strengthening Infectious Disease Preparedness
Malaysia remains on full preparedness for infectious disease threats, including hantavirus, with the Institute for Medical Research (IMR) utilizing Polymerase Chain Reaction (PCR) technology as the primary standard for disease detection.
How Meritplas Supports Medical Waste Management: Our biohazard bags are manufactured to meet the most stringent international standards for infection control. Featuring prominent biohazard symbol printing, color-coding according to international conventions (red, orange, yellow), superior strength and puncture resistance, and leak-proof construction, our biohazard bags help healthcare facilities comply with evolving regulations across the region. Our clinical waste bags provide secure containment for non-infectious clinical waste, supporting proper waste segregation at the source.
Healthcare Investment Surge – A Growing Market for Medical Packaging
The Southeast Asian healthcare sector is attracting unprecedented investment, signaling sustained growth in demand for specimen bags, specimen transport bags with pouch, lab packaging, and biohazard bags.
Major Investments in 2026
KKR has invested in Malaysia's Avisena Healthcare, supporting the expansion of multi-specialty offerings and new greenfield hospitals in the Klang Valley.
Sunway's healthcare unit raised RM2.9 billion in an initial public offering – Malaysia's biggest listing in nine years.
TPG-backed Asia OneHealthcare has confidentially filed for an IPO in Kuala Lumpur, potentially raising as much as RM10 billion ($2.5 billion) .
The Malaysia Healthcare Masterplan 2026 (MYMT 2026) targets RM12 billion in healthcare revenue by 2030, representing a compound annual growth rate of 32%.
The Critical Role of Specimen Bags and Biohazard Bags in Infection Control
As Southeast Asia's healthcare and laboratory infrastructure expands, the importance of specimen bags, specimen transport bags with pouch, lab packaging, and biohazard bags in infection control cannot be overstated.
Specimen Bags – The Foundation of Safe Sample Collection
Specimen bags are essential for collecting, transporting, and storing biological samples – including blood, urine, tissue, and other clinical specimens. At Meritplas, our specimen bags are engineered with:
High-quality polyethylene materials – selected for strength, flexibility, and chemical resistance
Leak-proof seals – preventing the escape of liquid or semi-liquid specimens during transport
Tamper-evident features – ensuring sample integrity and chain-of-custody compliance
Clear labeling areas – allowing for proper patient identification and specimen documentation
Specimen Transport Bag with Pouch – Innovation in Sample Transport
The specimen transport bag with pouch represents a significant innovation in laboratory logistics. Featuring a separate, integrated pouch for storing accompanying documentation outside the main specimen compartment, this design offers:
Reduced contamination risk – documentation remains separate from the biological specimen
Improved chain of custody – requisition forms and patient information stay with the specimen
Enhanced efficiency – laboratory staff can access documentation without handling the specimen directly
Biohazard Bags – The First Line of Defense in Infection Control
Biohazard bags are the cornerstone of infection control in healthcare and laboratory settings. Our biohazard bags feature:
Prominent biohazard symbol – for immediate identification
Color-coded for safety – available in red, orange, and yellow
Superior strength and puncture resistance – engineered to withstand healthcare waste handling
Leak-proof construction – preventing escape of liquid infectious waste
Conclusion – Partnering for a Safer Healthcare Future
The year 2026 is a transformative year for healthcare and laboratory infrastructure across Southeast Asia. From new infectious disease laboratories and diagnostic innovations to strengthened medical waste regulations and unprecedented healthcare investment, the region is building a more resilient, responsive, and future-ready healthcare system.
At Merit Packaging Sdn Bhd (Meritplas) , we are proud to support this transformation with high-quality specimen bags, specimen transport bags with pouch, lab packaging, and biohazard bags that meet the highest standards of safety and infection control.
As healthcare facilities across Malaysia, Southeast Asia, and beyond continue to expand and modernize, Meritplas remains your trusted partner for reliable, compliant, and high-quality healthcare and laboratory packaging solutions.
Contact us today to learn more about how our specimen bags, specimen transport bags with pouch, lab packaging, and biohazard bags can support your healthcare and laboratory operations.
Frequently Asked Questions
Q: Why is infection control important in specimen bag manufacturing?
A: Infection control is critical because specimen bags and biohazard bags are the first line of defense against exposure to bloodborne pathogens and infectious materials. Poor-quality packaging can lead to leaks, tears, and contamination, putting healthcare workers, patients, and the community at risk.
Q: What is a specimen transport bag with pouch?
A: A specimen transport bag with pouch is a specialized bag featuring a separate, integrated pouch for storing accompanying documentation – such as patient records or test requisition forms – outside the main specimen compartment, reducing contamination risk and improving chain of custody.
Q: How do new medical waste regulations affect biohazard bag requirements?
A: New regulations across ASEAN – including Indonesia's electronic tracking requirements, Thailand's stricter emission standards, and Vietnam's thermal disinfection standards – require biohazard bags and clinical waste bags that meet higher standards of strength, leak-proof performance, and proper labeling (including biohazard symbols and color-coding).
Q: What standards do Meritplas specimen bags and biohazard bags meet?
A: Meritplas products are manufactured under ISO 9001:2015 certified quality management systems. Our specimen bags, specimen transport bags with pouch, lab packaging, and biohazard bags meet rigorous international standards for strength, leak-proof performance, and regulatory compliance.
Q: How is Southeast Asia's healthcare expansion driving demand for lab packaging?
A: With new laboratories opening across the region – including the Philippines' BSL-2 Infectious Disease Laboratory, Malaysia's RM175 million pathology laboratory, and Merck's expanded Singapore BioReliance laboratory – the demand for reliable lab packaging, specimen bags, and specimen transport bags with pouch is growing rapidly. Meritplas is positioned to meet this demand with a monthly production capacity of 1,000 metric tonnes.
Comments